Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and PBSCT in CLL
NCT00006390Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jul 2001
- Primary completion
- Dec 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Rate of stem cell graft without detectable leukemia cells, Ability to successfully mobilize stem cells and 2 more. Started Jul 2001; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00006390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006390.